Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
EPA for Metastasis Trial 2

trialsTrialActive

EPA for Metastasis Trial 2

aka EMT2

A phase 3 trial in colorectal cancer, run by Mark A Hull, PhD FRCP, active but no longer recruiting.

Overview Notes Connected2

Overview

EPA for Metastasis Trial 2 is a phase 3, randomised interventional study registered as NCT03428477 by Mark A Hull, PhD FRCP, with a registry enrolment figure of 418 participants, started 2018-05-02 and due to reach its primary completion in 2025-11-30. Interventions recorded: Icosapent Ethyl; Placebo. Conditions listed: Liver Metastasis; Colon Cancer. Primary outcome: Progression Free Survival (PFS). Colorectal eligibility wording from the registry: "* Histological diagnosis of colorectal cancer with evidence of liver metastases". Sites: United Kingdom. United Kingdom sites listed: 13. No results are recorded here; the registry entry is the source.

Setting

A Randomised Placebo-controlled Phase III Trial of the Effect of the Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) on Colorectal Cancer Recurrence and Survival After Surgery for Resectable Liver Metastases

Phase

Phase 3

Sponsor

Mark A Hull, PhD FRCP

Registry

Enrolled

418 enrolled

Notes

UK sites (registry): Oxford University Hospital NHS Foundation Trust (Oxford); Hampshire Hospitals NHS Foundation Trust (Basingstoke); Aintree University Hospitals NHS Foundation Trust (Aintree); University Hospitals Birmingham NHS Foundation Trust (Birmingham); Cambridge UniversityHospitals NHS Foundation Trust (Cambridge); University Hospital of Wales (Cardiff); Leeds Teaching Hospitals NHS Foundation Trust (Leeds); King's College London (London); Royal Free London NHS Foundation Trust (London); Newcastle Upon Tyne Hospitals NHS Foundation Trust (Newcastle); Nottingham University Hospitals NHS Trust (Nottingham); Sheffield Teaching Hospitals NHS Foundation Trust (Sheffield) and 1 more.

Connected

Similar pages

not linked directly; found by shared links

Trial
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
COLLISION RELAPSE Trial
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.

cancers

1

Colon cancer (adenocarcinoma of the colon)

terms

1

Colorectal cancer trials open today (registry snapshot)

Evidence strength43/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 3+30
418 enrolled+13
No structured primary endpoint0
Result: active0
No independent replication recorded0

Formula disclosed on the evidence page.

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources & links

ClinicalTrials.gov NCT03428477

colorectal-deep-dive

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Colon cancer (adenocarcinoma of the colon)

Machine-readable versions of EPA for Metastasis Trial 2

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct03428477/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct03428477.

WebMCP tools registered on this page: onco_search, onco_get_entity.